ArticleBMC infectious diseases2026
Molecular diagnosis of HTLV-1 and HCV infection in polytransfused sickle cell disease in Kinshas: case of CMMASS.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextSickle cell patients present with permanent hemolytic anemia very often requiring transfusions. These transfusions put sickle cell patients at risk of HTLV-1 and HCV infection.
objectiveTo determine the prevalence of HTLV-1 and HCV infection among polytransfused sickle cell patients in Kinshasa.
methodsThis is a cross-sectional study with a descriptive aim in polytransfused sickle cell patients followed at the SS Mixed Medicine Center for Anemia (CMMASS). The parameters of interest were age, gender, number of transfusions. Molecular diagnosis of HTLV-1 and HCV was carried out by conventional amplification.
resultsThe median age of polytransfused sickle cell patients is 29 years. The female gender is in the majority 51.1% and the median number of transfusions is 24. A little over 11% of polytransfused sickle cell patients are infected with HCV, with a female predominance of 80%. Additionally, 60% of HCV-infected cases received between 2 and 19 transfusions. Approximately 5.5% of polytransfused sickle cell recipients are infected with HTLV-1, with the infection showing a female predominance of 80%. Most cases (80%) have received more than 20 transfusions. Coinfection with HCV and HTLV-1 occurs in about 2.2% of polytransfused sickle cell patients, representing 2/90 individuals. The 2 cases are female and are all aged 26. They received more than 20 transfusions at 80%.
conclusionPolytransfused sickle cell patients are a population at risk for HCV (11.1%) and HTLV-1 (5.5%) infections. Hence the need to introduce molecular tests and leukoreduction into transfusion safety (leukoreduction doesn’t prevent HCV and HTLV transfusion transmission). CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.